Render Target: STATIC
Render Timestamp: 2024-11-19T12:03:02.262Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-20 06:23:30.648
Product last modified at: 2024-08-30T23:15:07.835Z
View Featured Offers >>
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72
  1. Products /
  2. Activators & Inhibitors /
  3. SRPIN340

SRPIN340 #62630

    Product Information

    Product Usage Information

    SRPIN340 is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 1.43 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 349.4 g/mol
    Purity >98%
    Molecular Formula C18H18F3N3O
    CAS 218156-96-8
    Solubility Soluble in DMSO at 40 mg/mL or ethanol at 25 mg/mL.

    Background

    Serine/arginine-rich protein-specific kinases (SRPKs) 1 and 2 phosphorylate and regulate serine/arginine-rich (SR) proteins that bind and regulate mRNA splicing, playing an important role in post-transcriptional regulation (1). The small-molecule SRPIN340 is an SRPK inhibitor that is highly selective for SRPK1 (Ki = 0.89 mM) and SRPK2. SRPK dysregulation can alter SR protein activity and promote expression of splicing isoforms, leading to increased viral infection or tumorigenic processes. Inhibition of SRPK1 and SRPK2 by SRPIN340 reduces SRp75 protein phosphorylation, leading to suppressed Sindbis virus propagation and reduced HIV production (2). Dose-dependent suppression of hepatitis C virus replication by the inhibitor SRPIN340 has been seen in vitro (1). SRPIN340 treatment of leukemia cells triggered early and late events of apoptosis, and reduced myeloid and lymphoid leukemia cell viability (3). Suppression of VEGF by SRPIN340 inhibited choroidal neovascularization formation in a mouse model, suggesting a possible role for SRPIN340 in treating neovascular age-related macular degeneration (4).

    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.